IMR Press / RCM / Volume 24 / Issue 12 / DOI: 10.31083/j.rcm2412373
Open Access Review
Landscape of Statin as a Cornerstone in Atherosclerotic Cardiovascular Disease
Show Less
1 State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 100037 Beijing, China
*Correspondence: qianjfw@163.com (Jie Qian); lijianjun938@126.com (Jian-Jun Li)
Rev. Cardiovasc. Med. 2023, 24(12), 373; https://doi.org/10.31083/j.rcm2412373
Submitted: 11 September 2023 | Revised: 24 October 2023 | Accepted: 10 November 2023 | Published: 29 December 2023
Copyright: © 2023 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.
Abstract

Atherosclerosis, the key pathogenesis of cardiovascular disease, is a leading cause of death and disability worldwide. Statins are first-line lipid-lowering drugs, which have been demonstrated to be powerful agents for anti-atherosclerosis. Numerous studies have confirmed the cardiovascular benefits and long-term safety of statins in a wide range of patients. Statins play an indispensable and irreplaceable part in the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD). In this article, we summarize the evolution of statins and their role in the treatment of cholesterol. The anti-atherosclerotic mechanism of statins, its efficacy, safety and clinical outcomes in secondary and primary prevention of ACSVD in different patient populations, the combination treatment effects, and guideline recommendations are also detailed. This paper highlights the profound significance of statins as the most successful anti-atherogenic drug in the cardiovascular field.

Keywords
statins
cardiovascular disease
lipid-lowering
cornerstone
Funding
2022-12M-C&T-B-043/CAMS Innovation Fund for Medical Sciences (CIFMS)
Figures
Fig. 1.
Share
Back to top